Brief: Shenzhen Hepalink Pharmaceutical Sees FY Net Profit Attributable
28/01/2022 14:21
Jan 28 (Reuters) - Shenzhen Hepalink Pharmaceutical Group Co
Ltd 002399.SZ :
* SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO LTD SEES FY NET
PROFIT
ATTRIBUTABLE RMB275.0 MILLION TO RMB412.5 MILLION
* SHENZHEN HEPALINK PHARMACEUTICAL -EXPECTED RESULT AS
INCOME OF
COMPANY'S HEPARIN INDUSTRY CHAIN ACHIEVED GROWTH, AMONG OTHERS
Source text for Eikon: ID:
Further company coverage: 002399.SZ
(Reuters.briefs@thomsonreuters.com)
Recent news on Shenzhen Hepalink Pharmaceutical Co
See all newsBrief: Shenzhen Hepalink Pharmaceutical Group Says Enoxaparin Sodium Injection Obtains New Manufacturer Authorization From EMA
Brief: Shenzhen Hepalink Pharmaceutical Group Posts QTRLY Net Profit Attributable Of RMB156.6 Million
Brief: Shenzhen Hepalink Pharmaceutical Posts Profit Attributable RMB646.7 Million For Year
Brief: Shenzhen Hepalink Pharmaceutical Says Enoparin Approved In Argentina
Brief: Shenzhen Hepalink Pharmaceutical Says H1710 Injection Received Approval For From NMPA